作者
Bridget A Quinn, Rupesh Dash, Belal Azab, Siddik Sarkar, Swadesh K Das, Sachin Kumar, Regina A Oyesanya, Santanu Dasgupta, Paul Dent, Steven Grant, Mohamed Rahmani, David T Curiel, Igor Dmitriev, Michael Hedvat, Jun Wei, Bainan Wu, John L Stebbins, John C Reed, Maurizio Pellecchia, Devanand Sarkar, Paul B Fisher
发表日期
2011/10/1
来源
Expert opinion on investigational drugs
卷号
20
期号
10
页码范围
1397-1411
出版商
Taylor & Francis
简介
Introduction: Human cancers are genetically and epigenetically heterogeneous and have the capacity to commandeer a variety of cellular processes to aid in their survival, growth and resistance to therapy. One strategy is to overexpress proteins that suppress apoptosis, such as the Bcl-2 family protein Mcl-1. The Mcl-1 protein plays a pivotal role in protecting cells from apoptosis and is overexpressed in a variety of human cancers.
Areas covered: Targeting Mcl-1 for extinction in these cancers, using genetic and pharmacological approaches, represents a potentially effectual means of developing new efficacious cancer therapeutics. Here we review the multiple strategies that have been employed in targeting this fundamental protein, as well as the significant potential these targeting agents provide in not only suppressing cancer growth, but also in reversing resistance to conventional cancer treatments.
Expert …
学术搜索中的文章
BA Quinn, R Dash, B Azab, S Sarkar, SK Das, S Kumar… - Expert opinion on investigational drugs, 2011